Original Article

You have full text access to this OnlineOpen article

Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy

  1. Giuseppe Aprile MD1,
  2. Marco Ramoni PhD2,
  3. Dorothy Keefe MD3,
  4. Stephen Sonis DMD, DMSc1,†,*

Article first published online: 26 NOV 2007

DOI: 10.1002/cncr.23182

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 284–292, 15 January 2008

Additional Information

How to Cite

Aprile, G., Ramoni, M., Keefe, D. and Sonis, S. (2008), Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer, 112: 284–292. doi: 10.1002/cncr.23182

Author Information

  1. 1

    Division of Oral Medicine, Brigham and Women's Hospital and the Dana Farber Cancer Institute, Boston, Massachusetts

  2. 2

    Division of Health Sciences and Technology, Harvard Medical School and Massachusetts Institute of Technology, Boston, Massachusetts

  3. 3

    Department of Medical Oncology, Royal Adelaide Hospital and Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia

  1. †

    Fax (617) 232-8970.

*Division of Oral Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 26 NOV 2007
  3. Manuscript Accepted: 21 AUG 2007
  4. Manuscript Revised: 15 AUG 2007
  5. Manuscript Received: 7 MAR 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (232K)

REFERENCES

  • 1
    Bang SM,Park SH,Kang HG, et al. Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer. 2005; 13: 515–521.
  • 2
    Gunnars B,Nygren P,Glimelius B, et al. Assessment of quality of life during chemotherapy. Acta Oncol. 2001; 40: 175–184.
  • 3
    Hassett MJ,O'Malley AJ,Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006; 98: 1108–1117.
  • 4
    Ozer H. The timing of chemotherapy-induced neutropenia and its clinical and economic impact. Oncology. 2006; 5: 11–15.
  • 5
    Iop A,Manfredi AM,Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol. 2004; 15: 712–720.
  • 6
    Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004; 2: 3–8.
  • 7
    Hesketh PJ,Batchelor D,Golant M, et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004; 12: 543–549.
  • 8
    Kris MG,Hesketh PJ,Sommerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24: 2932–2947.
  • 9
    Kuhn JG. Chemotherapy-associated hematopoietic toxicity. Am J Health Syst Pharm. 2002; 59: 64–67.
  • 10
    Carr DB,Goudas LC,Balk EM, et al. Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr. 2004; 32: 23–31.
  • 11
    Miaskowski C,Dodd M,Lee K. Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monogr. 2004; 32: 17–21.
  • 12
    Dodd MJ,Miaskowsky C,Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001; 28: 465–470.
  • 13
    Wilmoth MC,Coleman EA,Smith SC, et al. Fatigue, weight gain, and altered sexuality in patients with breast cancer: exploration of a symptom cluster. Oncol Nurs Forum. 2004; 31: 1069–1075.
  • 14
    Cleeland CS,Mendoza TR,Wang WS, et al. Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory. Cancer. 2000; 89: 1634–1646.
    Direct Link:
  • 15
    Walsh D,Rybicki L. L. Symptom clustering in advanced cancer. Support Care Cancer. 2006; 14: 831–836.
  • 16
    Homsi J,Walsh D,Nelson KA, et al. The impact of palliative medicine consultation service in medical oncology. Support Care Cancer. 2002; 10: 337–342.
  • 17
    Kass RE,Raftery AE. Bayes factor. J Am Stat Assoc. 1995; 90: 773–795.
  • 18
    Beck SL,Schwartz AL. Unrelieved pain contributes to fatigue and insomnia. Oncol Nurs Forum. 2000; 27: 350.
  • 19
    Fleishman SB. Treatment of symptom cluster: pain, depression and fatigue. J Natl Cancer Inst Monogr. 2004; 32: 119–123.
  • 20
    Kirkova J,Davis MP,Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006; 24: 1459–1473.
  • 21
    Dodd MJ,Miaskowski C,Lee KA. Occurrence of symptom clusters. J Natl Cancer Inst Monogr. 2004; 32: 76–78.
  • 22
    Cleeland CS. Cancer-related symptoms. Semin Radiat Oncol. 2000; 10: 175–190.
  • 23
    Chen ML,Tseng HC. Symptom cluster in cancer patients. Support Care Cancer. 2006; 14: 825–830.
  • 24
    Cleeland CS. Cancer-related fatigue: new direction for research. Cancer. 2001; 92: 1657–1661.
    Direct Link:
  • 25
    Cleeland CS,Bennett GJ,Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biological mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003; 97: 2919–2925.
    Direct Link:
  • 26
    Barsevick A,Whitmer K,Nail LM, et al. Symptom cluster research: conceptual, design, measurement, and analysis issues. J Pain Symptom Manage. 2006; 31: 85–95.
  • 27
    Coyle N,Adelhardt J,Foley KM, et al. Character of terminal illness in the advanced cancer patients. J Pain Symptom Manage. 1990; 5: 83–93.
  • 28
    Huang RS,Kistner EO,Bleibel WK, et al. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther. 2007; 6: 31–36.
View Full Article (HTML) Get PDF (232K)